CellaVision, which develops and sells products for the routine analysis of blood and other body fluids in the clinical laboratory, launches its blog CellaVision News Blast at http://blog.cellavision.com today. At the blog, CellaVision will publish scientific papers in the field of cell morphology, as well as industry and product news. CellaVision has formed an international editorial board of experts in Hematology as a source for high quality content.
"With the blog as an information channel, we hope to provide laboratories and industry media with information about interesting discoveries and experiences in cell morphology, as well as give them an opportunity to comment on and share the material. It is also a way for CellaVision to monitor trends and debates in the industry, engage in dialogue with our customers and to follow the developments in cell morphology and digital images", says Yvonne Mårtensson, CellaVision's CEO.
The Editorial Board is currently composed of eight experts in hematology and cell morphology from hospital laboratories in North America, Europe and Japan. The blog's first article is posted by Jürgen Riedl and his colleagues from the Albert Schweitzer Hospital, Dordrecht in the Netherlands and highlights acute myeloid leukemia (AML), a form of cancer affecting adults.
For further information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Telephone: +46 708 33 77 82. E-mail: email@example.com
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2009 sales were SEK 109 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq, OMX Stockholm, Small Cap list. Read more at www.cellavision.com.